Abstract:e16037 Background: Recent studies revealed chemotherapy increases anti-PD1 response of gastric cancer (GC) by reducing myeloid-derived suppressor cells (MDSCs). However, a more specific MDSC-targeted treatment is needed to further improve anti-PD1 efficacy in advanced GC. Trefoil factor family 2 (TFF2), a partial agonist of CXCR4 and a secreted anti-inflammatory peptide, can suppress MDSC expansion. Here, we developed a novel MDSC-targeted peptide TFF2-MSA and investigated whether it can synergize with anti-PD1 in syngeneic GC mouse models. Methods: Murine serum albumin (MSA) was fused to murine TFF2 to generate TFF2-MSA peptide with an extended serum half-life. ACKP (Atp4b-Cre; Cdh1-/-; LSL-KrasG12D; Trp53-/-) GC cells developed from a highly malignant diffuse GC mouse model were grafted subcutaneously into HDC-GFP transgenic mice in which the immunosuppressive histidine decarboxylase (HDC)-expressing myeloid cells were traced with GFP. These recipient mice then received either TFF2-MSA or anti-PD-1 antibody or both when tumors reached 150 mm 3 . At the endpoint, flow cytometry analysis was performed to examine immune profiles. In parallel, a group of the s.c. tumor bearing mice were followed up for survival differences in response to the treatments. In the orthotopic model, ACKP-luc cells were implanted to stomach submucosa, and recipient mice received the same treatments started after 1 week. In the metastasis model, subcutaneous flank tumors were resected in ACKP-grafted mice once tumors reached 500 mm 3 to permit spontaneous lung metastasis, and mice then received the same treatments. Results: While either TFF2-MSA or PD-1 antibody showed little benefit as a single agent (TGI 15% and 25% respectively, p>0.05), their combination dramatically suppressed ACKP s.c. tumor growth (TGI 78%, p<0.0001) and markedly prolonged median survival (64 days vs. 32.5 days in control) in a synergistic manner. The combination therapy efficiently reduced tumor HDC-GFP + MDSCs by 67%, and profoundly increased tumor-infiltrating cytotoxic CD8 + T cells by 18 fold. The myeloid/lymphoid progenitor and output ratio in the bone marrow were decreased by the combination, to a similar level of tumor-free mice. While standard chemotherapy (5-fluorouracil and oxaliplatin) showed no efficacy, adding chemotherapy to the combination further improved treatment efficacy (TGI 91%) and extended median survival to 73 days. In addition, in the orthotopic model, the TFF2-MSA/PD-1 antibody combination eradicated GC in 80% mice without recurrence compared to 0% with either monotherapy. Finally, the combination of TFF2-MSA/PD-1 antibody significantly reduced 80% lung metastasis (vs. control, p 0.05). Conclusions: Targeting MDSCs using TFF2-MSA synergizes with PD-1 blockade therapy in advanced and metastatic syngeneic mouse models of gastric cancer.

Molecular Mechanisms of Paclitaxel and Nm-3 on Human Gastric Cancer in A Severe Combined Immune Deficiency Mice Orthotopic Implantation Model

The Inhibiting Effect of Combination of Allicin with Paclitaxel on Proliferation of Gastric Cancer Cells and Promotion of Apoptosis

Subtypes of MDSCs in Mechanisms and Prognosis of Gastric Cancer and Are Inhibited by Epirubicin and Paclitaxel.

Targeting Therapy with Docetaxel Thermosensitive Nano-Micelles of Human Gastric Cancer Xenografts in Nude Mice

Effects of Paclitaxel Combined with Mir-200B on Proliferation and Invasion of Gastric Cancer Cell Line SGC-7901

Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer.

Expression and Underlying Roles of IGFBP-3 in Paclitaxel-Treated Gastric Cancer Sgc-7901 Cells

Experimental study of anti-gastric cancer effect of combined application of recombinant human endostatin and paclitaxel

Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer.

Effect of paclitaxel octreotide conjugate on human ovarian paclitaxel-resistant cell xenograft tumor model and the mechanism underlying reversal of paclitaxel resistance

Combination of Microtubule Associated Protein-Tau and Β-Tubulin III Predicts Chemosensitivity of Paclitaxel in Patients with Advanced Gastric Cancer.

The Relationships Between the Chemosensitivity of Human Gastric Cancer to Paclitaxel and the Expressions of Class III Β-Tubulin, MAPT, and Survivin

Effects of Hyperbaric Oxygen Combined with Paclitaxel on the Mouse Model of Cervical Cancer and Immune Regulation Factors

Effect of Exercise Conbined with Paclitaxel on Tumor Growth in 4T1 Mouse Breast Cancer Model

Effect of MDSC-targeted TFF2-MSA with PD-1 blockade therapy in advanced gastric cancer models.

Impact of Mice Apoptosis Antigen of Lung Cancer Induced by Paclitaxel on Function of Dendritic Cells

Experimental study on growth inhibition of Gefitinid combined with paclitaxel on esophageal carcinoma cells in vitro and in vivo

Camellia Nitidissima Chi Extract Potentiates the Sensitivity of Gastric Cancer Cells to Paclitaxel Via the Induction of Autophagy and Apoptosis

Paclitaxel Sensitizes Gastric Cancer Cells to TRAIL-induced Apoptosis

Establishment of Orthotopic Transplantation Model of MKN-45 Human Gastric Cancer and Evaluation of the Efficacy of Paclitaxel in This Model

Preparation of paclitaxel loaded PLGA microspheres and its efficacy in Hep-2 laryngeal squamous cell carcinoma-bearing nude mice